The American Drug Price Scam — How the System Was Built, Who Profited, and Why “Most-Favored Nation” Is an Admission, Not a Fix

February 7 2026

Ottawa, Ontario

For years, Americans have been told a comforting lie: that the reason they pay the highest drug prices in the world is because foreign countries are freeloading off U.S. innovation. That America subsidizes global medicine. That pharmaceutical companies are forced to make up their losses at home.

That story collapses the moment you look at the data.

Six of the ten largest pharmaceutical companies in the world are American. Not European. Not Canadian. Not Asian. American. These companies didn’t stumble into global dominance by accident. They rose to the top because the United States created the most profitable pharmaceutical market on Earth — and then protected it.

This wasn’t market failure. It was policy design. The U.S. government allowed a system where drug companies could charge whatever the market would bear, with no universal price negotiation, no meaningful price ceilings, and long, aggressively defended patent protections. Unlike every other major industrialized country, the U.S. historically prohibited its largest public payer, Medicare, from negotiating drug prices. It allowed direct-to-consumer pharmaceutical advertising. It tolerated patent evergreening. And it enforced these rules domestically and abroad through trade policy and intellectual property law.

The result was predictable.

The United States consumes a minority share of the world’s prescription drugs by volume, yet generates roughly half — and in some datasets more — of global pharmaceutical revenue. In other words, a relatively small share of global drug use produces a massively disproportionate share of global profits. American patients are not the world’s pharmacy. They are the world’s profit center.

This is not speculation. It’s arithmetic. So when Donald Trump says that Americans are being ripped off on drug prices, he is not wrong. American drug prices are two to four times higher than in peer countries for the same medicines. That fact is undisputed across the political spectrum.

But here’s the part that doesn’t get said out loud. Those prices didn’t happen despite the U.S. government. They happened because of it.

The pharmaceutical lobby is one of the most powerful and well-funded lobbying forces in Washington. Its influence is bipartisan and longstanding. It shaped the laws that made extreme pricing legal, durable, and enforceable. Politicians didn’t lose control of the system — they designed it, maintained it, and defended it, while taking industry money every step of the way.

That context matters when we talk about “Most-Favored Nation” pricing.

MFN sounds like a crackdown. It’s framed as fairness — Americans shouldn’t pay more than other countries for the same drugs. But MFN is not a punishment of foreign freeloaders. It’s a partial claw-back of profits that were extracted almost entirely from Americans under rules the U.S. government itself wrote.

MFN only exists because the system ran too hot for too long.

If MFN pricing were applied universally and permanently if American prices were truly aligned with those of peer countries ,the current pharmaceutical profit model would collapse. That’s why MFN is narrow, selective, executive-order-based, and reversible. It corrects symptoms without dismantling causes.

TrumpRx follows the same pattern.

TrumpRx does not restructure pharmaceutical power. It doesn’t impose price controls. It doesn’t force universal negotiation. It doesn’t touch patents. Instead, it redirects consumers toward direct-to-consumer purchasing pathways that cut out middlemen like pharmacy benefit managers and insurers.

That sounds adversarial. It isn’t.

When drugs are sold directly to consumers at manufacturer-set cash prices, pharmaceutical companies often preserve, or even improve their margins. They trade rebates and opaque negotiations for control and predictability. The visible price may drop, but the pricing power remains exactly where it always was: with the manufacturer.

TrumpRx helps some people. It lowers out-of-pocket costs for certain uninsured or cash-paying patients. But it does not change who pays, who profits, or who decides. It is a distribution workaround, not a power shift.

Put plainly: cutting out middlemen does not mean cutting out pharmaceutical dominance.

And that brings us to the uncomfortable conclusion policymakers avoid.

America’s drug pricing crisis is not the result of foreign exploitation. It is the result of domestic policy choices made over decades, reinforced by lobbying, and tolerated because the profits were enormous and politically useful.

Most-Favored Nation pricing isn’t a bold reform. It’s an admission. An acknowledgment that the system Americans were told was necessary has, in fact, been exploiting them all along.

The real question isn’t whether Americans have been overcharged.

The real question is how long the govern

ment plans to pretend it wasn’t complicit.

J.Bond

Fifth Pillar Media Group.